A carregar...
Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review
Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non-small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Several experimental studies hav...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8264346/ https://ncbi.nlm.nih.gov/pubmed/34295669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-124 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|